# Whey Protein Satiety Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/whey-protein-satiety-randomized-trial-evidence-review
Category: evidence-review
Summary: Whey Protein Satiety Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are r
Last reviewed: 2026-06-10
Reviewed by: Migaku Evidence Review
# Whey Protein Satiety Randomized Trial: What the Evidence Says

## Quick Answer

Whey Protein Satiety Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 randomized trial, 1 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| The Impact of Oral Whey Protein and Yeast Protein Supplementation for 6 Months on Skeletal Muscle Mass, Strength, and Function in the Elderly: A Randomized, Controlled, Parallel Study | randomized trial | 2 | 2026-03-13 | 10.1002/fsn3.71552 |
| Resistant Starch as a Functional Nutrient to Control Cardiometabolic Risk Factors in Humans: An Integrative Review | preclinical study | 4 | 2026-04-30 | 10.1007/s13668-026-00766-0 |

## What The Sources Report

- Accelerated global population aging has made the progressive decline in skeletal muscle mass and associated physical functional deterioration among older adults a major public health concern. [Huijing Bai (2026); evidence level 2]
- For instance, a UK study found that dynapenia (a key component of sarcopenia) was associated with markedly increased healthcare and social care costs, with annual additional medical expenses attributable to muscle weakness reaching £2.5 billion (Bruyère et al. ). [Huijing Bai (2026); evidence level 2]
- Their increasing prevalence has been strongly associated with the presence of multiple cardiometabolic risk factors-including elevated systolic blood pressure, high low-density lipoprotein cholesterol (LDL-c), elevated body mass index (BMI), and elevated fasting glucose-often exacerbated by unhealthy lifestyle behaviors such as physical inactivity and poor dietary habits. [Tavares Isabela Ribeiro Grangeira (2026); evidence level 4]
- According to the World Health Organization (WHO), these risk factors are interrelated and play a key role in the development of non-communicable diseases (NCDs), particularly cardiovascular diseases. [Tavares Isabela Ribeiro Grangeira (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For whey protein satiety randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Huijing Bai (2026). The Impact of Oral Whey Protein and Yeast Protein Supplementation for 6 Months on Skeletal Muscle Mass, Strength, and Function in the Elderly: A Randomized, Controlled, Parallel Study. DOI: 10.1002/fsn3.71552. PMCID: PMC13093566. PMID: 42016236. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13093566/
- Tavares Isabela Ribeiro Grangeira (2026). Resistant Starch as a Functional Nutrient to Control Cardiometabolic Risk Factors in Humans: An Integrative Review. DOI: 10.1007/s13668-026-00766-0. PMCID: PMC13133204. PMID: 42060241. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13133204/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.